E
Enliven Therapeutics, Inc.
ELVN · NASDAQ · Healthcare · 4.2B
Closing price
$40.98
+0.86% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
5.1×
Enterprise value / EBITDAEV/EBITDA
-21.5×
Free cash flow yieldFCF yield
-3.0%
Return on equityROE
-22.6%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
1.0×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.